SM-102 is an ionizable cationic lipid that has been used to generate lipid nanoparticles (LNPs) for the in vivo and in vitro delivery of mRNA and plasmid DNA. SM-102 plays a key role in COVID-19 mRNA vaccines, demonstrating excellent in vivo delivery efficiency and good safety globally.

Protheragen's Commercial LNP Kit is based on SM-102, significantly simplifying the LNP preparation process and has been clinically validated. Through a standardized preparation process, our Commercial LNP Kit can efficiently encapsulate various nucleic acid molecules such as mRNA and siRNA, aiming to help researchers conduct nucleic acid drug research more efficiently.

Core Advantages

• Excellent delivery performance
• Broad nucleic acid compatibility
• Standardized preparation process
• Stable and reproducible quality

Applications

• Nucleic acid drug screening
• Vaccine development
• Gene therapy

For more product information, please contact us. We are committed to providing comprehensive nucleic acid delivery solutions that significantly reduce R&D costs, allowing researchers to focus more of their energy on innovative research work.